Select publications

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc ASCO 2003;Abstract 1015.

Dunst J et al. Phase-II-study off preoperative chemoradiation with capecitabine in rectal cancer. Proc ASCO 2004;Abstract 3559.

Glynne-Jones R et al. A phase I study of preoperative radiation and capecitabine in combination with oxaliplatin in locally advanced rectal cancer. Proc ASCO 2003;Abstract 1174.

Hickish T et al. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. Proc ASCO 2004;Abstract 3619.

Hurwitz H et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 2003;Abstract 3646.

Kocakova I et al. Combined therapy of locally advanced rectal adenocarcinoma with capecitabine and concurrent radiotherapy. Proc ASCO 2003;Abstract 1295.

Lin EH et al. A phase II study of capecitabine and radiotherapy plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC): Preliminary safety analysis. Proc ASCO 2003;Abstract 1152.